MRI (magnetic resonance imaging) agent OptiMARK approved:
This article was originally published in Clinica
Executive Summary
Mallinckrodt's MRI contrast agent for brain, spine and liver imaging, OptiMARK, has been cleared for sale in the US. The St Louis, Missouri-based company said the agent, which will be on sale in the first quarter of 2000, will be in a $150 million market experiencing 12%-15% growth per year.